Winslow Evans & Crocker’s Alexion Pharmaceuticals ALXN Stock Holding History

Winslow Evans & Crocker’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	$63K	Hold	403	–	–	0.01%	548
2020 Q3	$47K	Hold	403	–	–	0.01%	471
2020 Q2	$45K	Sell	403 -1	-0.2%	-$106	0.01%	478
2020 Q1	$38K	Hold	404	–	–	0.01%	476
2019 Q4	$46K	Hold	404	–	–	0.01%	523
2019 Q3	$42K	Hold	404	–	–	0.01%	532
2019 Q2	$56K	Sell	404 -12	-3%	-$1.55K	0.02%	489
2019 Q1	$58K	Buy	416 +12	+3%	+$1.49K	0.02%	469
2018 Q4	$42K	Hold	404	–	–	0.01%	496
2018 Q3	$58K	Hold	404	–	–	0.02%	459
2018 Q2	$52K	Hold	404	–	–	0.02%	488
2018 Q1	$44.9K	Hold	404	–	–	0.01%	503
2017 Q4	$48.2K	Hold	404	–	–	0.02%	500
2017 Q3	$56.5K	Buy	404 +1	+0.2%	+$136	0.02%	451
2017 Q2	$49K	Sell	403 -1	-0.2%	-$116	0.01%	560
2017 Q1	$48.9K	Hold	404	–	–	0.02%	542
2016 Q4	$49.3K	Hold	404	–	–	0.02%	539
2016 Q3	$49.4K	Buy	404 +250	+162%	+$32.2K	0.01%	543
2016 Q2	$17.9K	Buy	154 +1	+0.7%	+$142	0.01%	724
2016 Q1	$21.3K	Sell	153 -1	-0.6%	-$147	0.01%	689
2015 Q4	$29.2K	Hold	154	–	–	0.01%	655
2015 Q3	$23.9K	Hold	154	–	–	0.01%	676
2015 Q2	$27.7K	Hold	154	–	–	0.01%	687
2015 Q1	$26.5K	Sell	154 -2,710	-95%	-$491K	0.01%	671
2014 Q4	$530K	Buy	2,864 +2,710	+1,760%	+$502K	0.15%	153
2014 Q3	$25.4K	Buy	154 +1	+0.7%	+$164	0.01%	687
2014 Q2	$23.9K	Hold	153	–	–	0.01%	636
2014 Q1	$23.3K	Hold	153	–	–	0.01%	633
2013 Q4	$20K	Buy	+153	New	+$18.4K	0.01%	708

Other funds holding ALXN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Winslow Evans & Crocker's ALXN Position: Q4 2020 in Review

Winslow Evans & Crocker held its Alexion Pharmaceuticals (ALXN) position steady in Q4 2020 at 403 shares worth $63K. The position accounts for 0.01% of the portfolio, ranked #548.

Winslow Evans & Crocker first reported a position in ALXN in Q4 2013 and has held it in 29 quarters since. The position peaked at $530K in Q4 2014. 827 funds tracked by Wall St. Rank hold ALXN as of Q4 2020.

Winslow Evans & Crocker held 403 shares of Alexion Pharmaceuticals worth $63K as of Q4 2020.
Winslow Evans & Crocker left its Alexion Pharmaceuticals share count unchanged in Q4 2020.
Alexion Pharmaceuticals made up 0.01% of Winslow Evans & Crocker's portfolio in Q4 2020, its #548 holding.
Winslow Evans & Crocker first reported a position in Alexion Pharmaceuticals in Q4 2013 and has held it in 29 quarters since.
Winslow Evans & Crocker's Alexion Pharmaceuticals position peaked at $530K in Q4 2014.
827 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2020.

Based on Winslow Evans & Crocker's 13F filing for Q4 2020, filed 3 Feb 2021.